Mustang Bio to Participate in Two August 2023 Investor Conferences
03 août 2023 08h00 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023
02 août 2023 16h01 HE
|
Journey Medical Corporation
Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET Company and Neal Bhatia, MD, Director of Clinical Dermatology,...
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
01 août 2023 08h30 HE
|
Avenue Therapeutics
MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
31 juil. 2023 08h30 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
27 juil. 2023 08h30 HE
|
Avenue Therapeutics
MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
27 juil. 2023 07h00 HE
|
Checkpoint Therapeutics, Inc
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a...
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
25 juil. 2023 08h30 HE
|
Avenue Therapeutics
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
19 juil. 2023 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., July 19, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
11 juil. 2023 08h30 HE
|
Journey Medical Corporation
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues DFD-29 demonstrated statistical...
Mustang Bio Announces Participation in Upcoming Scientific Meetings
06 juil. 2023 08h00 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...